Next Article in Journal
Acknowledgement to Reviewers of Veterinary Sciences in 2015
Next Article in Special Issue
Comparative Aspects of Canine Melanoma
Previous Article in Journal / Special Issue
Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach
Article Menu

Export Article

Open AccessReview
Vet. Sci. 2016, 3(1), 4; doi:10.3390/vetsci3010004

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer

Virginia Maryland College of Veterinary Medicine, 245 Duck Pond Dr., Blacksburg, VA 24061, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Jaime F. Modiano
Received: 8 September 2015 / Revised: 12 January 2016 / Accepted: 18 January 2016 / Published: 20 January 2016
(This article belongs to the Special Issue Comparative Pathogenesis of Cancers in Animals and Humans)
View Full-Text   |   Download PDF [511 KB, uploaded 20 January 2016]   |  

Abstract

Conventional cytotoxic chemotherapy involving DNA-interacting agents and indiscriminate cell death is no longer the future of cancer management. While chemotherapy is not likely to completely disappear from the armamentarium; the use of targeted therapies in combination with conventional treatment is becoming the standard of care in human medicine. Tyrosine kinases are pivotal points of functional cellular pathways and have been implicated in malignancy, inflammatory, and immune-mediated diseases. Pharmaceutical interventions targeting aberrant tyrosine kinase signaling has exploded and is the second most important area of drug development. The “Valley of Death” between drug discovery and approval threatens to blunt the enormous strides in cancer management seen thus far. Kinase inhibitors, as targeted small molecules, hold promise in the treatment and diagnosis of cancer. However, there are still many unanswered questions regarding the use of kinase inhibitors in the interpretation and management of cancer. Comparative oncology has the potential to address restrictions and limitations in the advancement in kinase inhibitor therapy. View Full-Text
Keywords: tyrosine kinase inhibitors; comparative; cancer; chemotherapy; dog; cat; human tyrosine kinase inhibitors; comparative; cancer; chemotherapy; dog; cat; human
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Dervisis, N.; Klahn, S. Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer. Vet. Sci. 2016, 3, 4.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vet. Sci. EISSN 2306-7381 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top